Free Trial
One Day Left! MarketBeat All Access Returns to $249 Soon
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Don't Miss Out
Claim MarketBeat All Access Sale Promotion
NASDAQ:URGN

Urogen Pharma Q3 2026 Earnings Date & Estimates

Urogen Pharma logo
$33.75 -0.16 (-0.47%)
Closing price 10/28/2026 04:00 PM Eastern
Extended Trading
$33.87 +0.12 (+0.36%)
As of 08:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Urogen Pharma is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 10:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
10:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Urogen Pharma in Q3 2026

Urogen Pharma is expected to post earnings of $0.10 per share on revenue of $90.58 million. In the same quarter a year earlier Urogen Pharma reported -$0.69 per share on revenue of $27.48 million. Urogen Pharma last reported on August 5, 2026, posting -$0.28 per share and missing the -$0.2650 consensus estimate. Urogen Pharma has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.10
Expected Revenue
$90.58 million
Prior-Year EPS
-$0.69
Prior-Year Revenue
$27.48 million
Expected Revenue Growth
+229.6%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.28 (Missed by -$0.0150)
Last Quarter Revenue
$72.46 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Urogen Pharma Q3 2026 Earnings FAQ

Urogen Pharma (NASDAQ:URGN) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Urogen Pharma's Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 10:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Urogen Pharma to post earnings of $0.10 per share for Q3 2026.

The consensus revenue estimate for Urogen Pharma is $90.58 million for Q3 2026.

Urogen Pharma Earnings Headlines

UroGen's Zusduri Offers Early Innings Opportunity, Oppenheimer Says
October 28 at 3:36 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/urogen-apos-zusduri-offers-early-163852220.html
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
October 28 at 10:35 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/urogen-s-final-results-from-olympus-five-year-follow-up-study-reinforces-durable-response-with-jelmyto-in-patients-with-low-grade-upper-tract-urothelial-cancer-1036676573
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
October 29 at 1:00 AM  |  Porter & Company (Ad)
UroGen Reports No High-Grade Disease Progression In Five-Year JELMYTO Follow-Up; Stock Down
October 28 at 10:35 AM  |  rttnews.comhttps://www.rttnews.com/3704489/urogen-reports-no-high-grade-disease-progression-in-five-year-jelmyto-follow-up-stock-down.aspx
UroGen's Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
October 28 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390117/0/en/urogen-s-final-results-from-olympus-five-year-follow-up-study-reinforces-durable-response-with-jelmyto-in-patients-with-low-grade-upper-tract-urothelial-cancer.html
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
October 27 at 6:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/27/3389774/0/en/urogen-pharma-to-report-third-quarter-2026-financial-results-on-wednesday-november-4th-2026.html
See More Urogen Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Urogen Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Urogen Pharma and other key companies, straight to your email.

About Urogen Pharma

Urogen Pharma (NASDAQ:URGN) Ltd. (NASDAQ: URGN) is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. The company’s therapies are designed to deliver medicines directly to the affected area, with the goal of improving drug exposure while limiting systemic side effects.

UroGen’s primary commercial product is Jelmyto, a mitomycin-based treatment approved in the United States for adults with low-grade upper tract urothelial cancer. Jelmyto uses UroGen’s proprietary RTGel technology, which forms a gel in the urinary tract and enables the sustained local release of mitomycin.

The company has also developed UGN-102, an investigational mitomycin-based reverse thermal gel intended for the treatment of low-grade, intermediate-risk non-muscle-invasive bladder cancer. UroGen’s development programs and commercial activities primarily serve patients and healthcare providers in the United States, with a focus on urologic oncology.

View Urogen Pharma Profile
Earnings Tools